Post-ASCO 2024 Breast Cancer Highlights

Interactive webinar featuring presentations & discussions on selected abstracts from ASCO 2024
Chair: Dr Sara Tolaney | Moderator: Professor Giuseppe Curigliano & Dr Erika Hamilton
21 June | 08:00–10:30 CDT/ 14:00–16:30 BST/ 15:00–17:30 CEST

This webinar is for HCPs and allied health professionals only. Please apply for registration and we’ll confirm your application once received.

Agenda

Timings are in CDT

08:00–08:05 | Session 1: Latest in ctDNA and patient stratification

• Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER) – #505: Kevin Kalinsky

08:05–08:25 | Panel discussion

08:25–09:10| Session 2: Advances with antibody-drug conjugates

• Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06) – #LBA1000: Giuseppe Curigliano
• SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer – #LBA1004: Ana Garrido-Castro
• TBCRC 048 (olaparib expanded) expansion cohorts: Phase 2 study of olaparib monotherapy in patients (pts) with metastatic breast cancer (MBC) with germline (g) mutations in PALB2 or somatic (s) mutations in BRCA1 or BRCA2 – #1021: Nadine Tung
• A-BRAVE trial: A phase III randomized trial with avelumab in early triple-negative breast cancer with residual disease after neoadjuvant chemotherapy or at high risk after primary surgery and adjuvant chemotherapy – #LBA500: Pierfranco Conte
• Enfortumab vedotin (EV) in triple-negative breast cancer (TNBC) and HR+/HER2- breast cancer (BC) cohorts of EV-202 –#1005: Antonio Giordano
• DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC – #1009: Komal Jhaveri
• Rates of pathologic complete response (pCR) after neoadjuvant datopotamab deruxtecan (Dato): Results from the I-SPY2.2 trial – #LBA509: Jane Meisel

09:10–09:30 | Panel discussion

09:30–09:50 | Session 3: Novel endocrine therapy combination approaches

• First-line inavolisib/placebo + palbociclib + fulvestrant (Inavo/Pbo+Palbo+Fulv) in patients (pts) with PIK3CA-mutated, hormone receptor-positive, HER2 negative locally advanced/metastatic breast cancer who relapsed during/within 12 months (mo) of adjuvant endocrine therapy completion: INAVO120 Phase III randomized trial additional analyses – #1003: Dejan Juric
• Primary results from PATRICIA cohort C (SOLTI-1303), a randomized phase II study evaluating palbociclib with trastuzumab and endocrine therapy in pretreated HER2-positive and PAM50 luminal advanced breast cancer – #1008: Eva Ciruelos
• Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial – #LBA1001: Kevin Kalinsky

09:50–10:10 | Panel discussion

10:10–10:15 | Closing remarks & end of webinar

This webinar is for HCPs and allied health professionals only. Please apply for registration and we’ll confirm your application once received.